OSLO/LONDON, 4th July 2022: Reference is made to the announcement by EXACT
Therapeutics AS ('EXACT-Tx' or the 'Company') on 9 June 2022 regarding the
issuance of 5,052 new shares in the Company, for the purpose of issuing shares
under the Company's restricted stock unit (RSU) program to its Board members.

The share capital increase pertaining to the issuance of the new shares has now
been registered with the Norwegian Register of Business Enterprises. The
Company's new registered share capital is NOK 119,988.876 divided into
29,997,219 shares, each with a nominal value of NOK 0.004.

DISCLOSURE REGULATION This information is subject to the disclosure requirements
pursuant to Section 5-12 of the Norwegian Securities Trading Act.

ENDS

For more information, please contact:

Per Walday, CEO
EXACT Therapeutics
Email: per.walday@exact-tx.com

Dominic Moreland, CFO 
EXACT Therapeutics 
Email: Dominic@exact-tx.com

About EXACT-Tx
EXACT-Tx is a Norwegian clinical-stage precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101)
activated by ultrasound for enhanced drug targeting deployed in multiple
indications to enhance the therapeutic efficacy of medicines through the use of
ultrasound-mediated drug delivery, for patients across multiple diseases.
www.exact-tx.com

Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.